Shares of BioSante Pharmaceuticals were buoyed by the news that its vaccine adjuvant produced more bird flu antibodies in an animal study. BioVant is being developed with the company's calcium phosphate nanotechnology, which uses microscopic materials to deliver therapies. BioVant demonstrated steadily rising antibody levels over the 10 weeks of the study. Adjuvants are considered a vital ingredient in making bird flu vaccines effective for large numbers of people. Report